Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2009
06/16/2009US7547692 Rifamycin analogs and uses thereof
06/16/2009US7547691 Such as 2-{5-Methyl-2-[3-(4-methylpiperazin-1-yl)-propylamino]-pyrimidin-4-yl}-benzo[b]thiophene-4-carboxylic acid methylamide; inhibitory Kappa-B protein inhibitors (IKK); rheumatoid arthritis and chronic obstructive pulmonary disease
06/16/2009US7547690 Compounds for the treatment of Hepatitis C
06/16/2009US7547689 Motexafin gadolinium or lutetium for injection in sealed glass vial purged of oxygen; radiation sensitizer acts to catalyze the oxidation of NAD(P)H, ascorbate and other reducing agents
06/16/2009US7547688 Methods for treatment of nocturia
06/16/2009US7547687 Therapeutic treatment methods
06/16/2009US7547686 Combretastatin A-3 prodrug
06/16/2009US7547685 Therapeutic substituted pyrrolidone compounds
06/16/2009US7547684 (1R,3R,4R,7S)-7-[2-Cyanoethoxy(diisopropylamino)phosphinoxy]-1-[1-(S)-(4,4'-dimethoxytrityl)oxy-ethyl]-3-(uracil-1-yl)-2,5-dioxa-bicyclo[2.2.1]heptane; useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance
06/16/2009US7547682 Useful as a candidate for a vaccine against ticks, particularly Ornithodoros moubata, tick-borne infections such as rickettsiosis, filariasis, Q fever, African recurrent fever, or viral encephalitis
06/16/2009US7547681 Surface receptor antigen vaccines
06/16/2009US7547680 Benzimidazole derivatives and medical uses thereof
06/16/2009US7547679 Ether linked macrolides useful for the treatment of microbial infections
06/16/2009US7547678 Using expression vector comprising UDP-glucuronosyltransferase (UGTIAI) as gene transfer tool in treatment of hyperbilirubinemia
06/16/2009US7547673 Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
06/16/2009US7547660 Phenyl-substituted 4-hydroxy-tetrahydropyridones
06/16/2009US7547511 Antisense inhibition of laminin-8 expression to inhibit human gliomas
06/16/2009US7547452 Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
06/16/2009US7547451 Comprises core and enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a derivative thereof; treatment of ulcerative colitis and Crohn's disease
06/16/2009US7547444 Methods for controlling fungi and bacteria
06/16/2009US7547439 Elicit immune response from human lymphocytes when complexed with a major histocompatibility complex molecule type HLA-A2; polypeptide
06/16/2009US7547434 Compositions and methods for mitigating skin irritation
06/16/2009US7547433 Liquid formulations for the prevention and treatment of mucosal diseases and disorders
06/16/2009US7547274 Radioactive member and method of making
06/16/2009CA2591758C Applicator for the delivery of topical formulation into mucosal cavities
06/16/2009CA2574904C Antiretroviral enantiomeric nucleotide analogs
06/16/2009CA2534961C Process for the recovery of a phytolipid composition
06/16/2009CA2487365C Piperidine derivatives as potassium channel blockers
06/16/2009CA2452217C Hiv inhibiting pyrimidines derivatives
06/16/2009CA2451474C Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
06/16/2009CA2444818C Utilization of galanthamine for the treatment of pathologies of the central nervous system owing to intoxications with psychotropic substances
06/16/2009CA2434187C Androgenic 7-substituted 11-halogenated steroids
06/16/2009CA2415154C Modified release formulations of selective serotonin re-uptake inhibitors
06/16/2009CA2405136C Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
06/16/2009CA2399910C Mammalian secreted group iii phospholipase a2
06/16/2009CA2396180C Stable aqueous deoxyfructosazine solution
06/16/2009CA2388314C Imidazole derivatives as phosphodiesterase vii inhibitors
06/16/2009CA2385995C Quinuclidine compound and medicament comprising the compound as active ingredient
06/16/2009CA2381097C Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents
06/16/2009CA2362082C 2-n-substituted or unsubstituted-2-amino-5-methylpiperidine-3,4-diols and process for the preparation thereof
06/16/2009CA2361936C Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
06/16/2009CA2357744C Potassium salt of (s)-omeprazole
06/16/2009CA2353063C Benzimidazole compounds that are vitronectin receptor antagonists
06/16/2009CA2347097C Process for purification of solvents useful in the preparation of pharmaceutical compositions
06/16/2009CA2343732C Substituted .gamma.-phenyl-.delta.-lactones and analogs thereof and uses related thereto
06/16/2009CA2340898C Compositions and methods for treating intracellular infections
06/16/2009CA2339996C Method for treating hot flashes in humans
06/16/2009CA2311742C 6-amino-9-benzyl-8-hydroxypurine derivatives
06/16/2009CA2284802C Substituted isoquinolines as ultra short acting neuromuscular blockers
06/16/2009CA2278201C Novel modifications to 2-amino-4-(4-fluorobenzylamino)-1-ethoxycarbonyl-aminobenzene, and processes for their preparation
06/16/2009CA2264750C Highly selective butyrylcholinesterase inhibitors for the treatment and diagnosis of alzheimer's disease and dementias
06/16/2009CA2243201C Process for producing sustained-release preparation
06/16/2009CA2202032C Agent for potentiating nerve growth factor activity containing 1,2-ethanediol derivative or salt thereof
06/12/2009CA2610813A1 Tropane alkaloids and trigonelline combinations and methods for administering the same
06/11/2009WO2009073885A1 Leukemic stem cell ablation
06/11/2009WO2009073878A1 Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin
06/11/2009WO2009073869A1 Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors
06/11/2009WO2009073843A1 Inhalable compositions having enhanced bioavailability
06/11/2009WO2009073835A1 Oral compositions of abt-263 for treating cancer
06/11/2009WO2009073818A1 Compounds and therapeutic use thereof
06/11/2009WO2009073788A1 Compositions and methods for treating menopausal females
06/11/2009WO2009073782A2 Apparatus and methods for treatment of pathologic proliferative conditions of uterine tissue
06/11/2009WO2009073780A1 Process for making macrocyclic oximyl hepatitis c protease inhibitors
06/11/2009WO2009073779A1 Gamma secretase modulators
06/11/2009WO2009073777A1 Gamma secretase modulators
06/11/2009WO2009073772A1 Novel seh inhibitors and their use
06/11/2009WO2009073757A1 Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3] dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl) benzoic acid
06/11/2009WO2009073756A1 Combination therapies using melengestrol acetate and zilpaterol or its salts
06/11/2009WO2009073719A1 Quinoxalinyl derivatives
06/11/2009WO2009073711A1 Improved formulations and methods for lyophilization and lyophilates provided thereby
06/11/2009WO2009073683A2 Methods of treating copd
06/11/2009WO2009073677A1 Fluoroalkyl tetrabenazine carbinol compounds as imaging agents and probes
06/11/2009WO2009073669A1 Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
06/11/2009WO2009073665A1 Acid mimic compounds for the inhibition of isoprenyl-s-cysteinyl methyltransferase
06/11/2009WO2009073661A2 Compositions comprising coenzyme q-io and garlic oil for an increased coenzyme q-10 bioavailability
06/11/2009WO2009073659A1 Compositions comprising coenzyme q-10 and garlic oil for an increased coenzyme q-10 bioavailability
06/11/2009WO2009073620A2 Ido inhibitors
06/11/2009WO2009073586A1 Methods using phosphatidylserine, lysophosphatidylserine, and/or salts thereof to increase testosterone levels
06/11/2009WO2009073564A1 Compositions and methods for treating lysosomal disorders
06/11/2009WO2009073527A2 Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
06/11/2009WO2009073517A2 Intravesical compositions with valrubicin for the treatment of bladder cancer
06/11/2009WO2009073508A2 Polysaccharide gel compositions and methods for sustained delivery of drugs
06/11/2009WO2009073460A2 Inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 for ocular neuroprotection
06/11/2009WO2009073437A1 Polysaccharide gel formulation
06/11/2009WO2009073432A1 Substituted cyclopentanes having prostaglandin activity
06/11/2009WO2009073300A1 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
06/11/2009WO2009073256A2 Optical atomic magnetometer
06/11/2009WO2009073224A1 Methods of treating certain diseases using pyrimidine derivatives
06/11/2009WO2009073215A1 Pharmaceutical compositions comprising nanoparticles and a resuspending material
06/11/2009WO2009073203A1 Trp-m8 receptor ligands and their use in treatments
06/11/2009WO2009073192A2 Systems and methods for delivery of materials
06/11/2009WO2009073186A1 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling
06/11/2009WO2009073184A1 Compositions for inducing labor and associated methods
06/11/2009WO2009073153A2 Small molecule myristate inhibitors of bcr-abl and methods of use
06/11/2009WO2009073148A2 Polymorphs of n-malonyl-bis(n'-methyl-n'-thiobenzoylhydrazide)
06/11/2009WO2009073147A2 Process for preparing bis(thiohydrazide amides)
06/11/2009WO2009073146A2 Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
06/11/2009WO2009073139A2 Combined treatment with an egfr kinase inhibitor and an inhibitor of c-kit
06/11/2009WO2009073138A2 Treatment of metabolic syndrome with novel amides
06/11/2009WO2009073118A1 Tryptamine sulfonamides as 5-ht6 antagonists